Provided by Tiger Trade Technology Pte. Ltd.

Castle Biosciences, Inc.

32.33
+0.01000.03%
Post-market: 32.330.00000.00%16:33 EDT
Volume:224.20K
Turnover:7.23M
Market Cap:987.67M
PE:-49.42
High:32.94
Open:32.77
Low:31.71
Close:32.32
52wk High:44.28
52wk Low:17.72
Shares:30.55M
Float Shares:28.22M
Volume Ratio:1.01
T/O Rate:0.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6542
EPS(LYR):-0.8334
ROE:-4.20%
ROA:-1.36%
PB:2.10
PE(LYR):-38.79

Loading ...

Castle Biosciences shareholders elect three directors at annual meeting

Reuters
·
May 30

Castle Biosciences price target lowered to $35 from $50 at KeyBanc

TIPRANKS
·
May 29

SEALSQ's QS7001 Post-Quantum Secure Element Achieves NIST SP 800-90B Entropy Source Validation, key milestone Toward FIPS 140-3 and Common Criteria EAL5+ Certification

GlobeNewswire
·
May 28

Castle Bio CEO Derek Maetzold disposes 4,477 shares worth $90,130.11

Reuters
·
May 23

Castle Biosciences to present at Jefferies Global Healthcare Conference

Reuters
·
May 13

Castle Biosciences Is Maintained at Buy by BTIG

Dow Jones
·
May 13

U.S. RESEARCH ROUNDUP-Aecom, Humana, Mosaic

Reuters
·
May 13

Castle Bio CEO Derek Maetzold disposes 11,397 shares for USD 254,409.06

Reuters
·
May 12

Castle Biosciences Down Over 15%, on Pace for Largest Percent Decrease Since July 2024 -- Data Talk

Dow Jones
·
May 07

Castle Biosciences (CSTL) Gets a Buy from Lake Street

TIPRANKS
·
May 07

Castle Biosciences Is Maintained at Outperform by Baird

Dow Jones
·
May 07

Sweden's SciBase Q1 sees margin pressure on currency impact

Reuters
·
May 07

SciBase Q1 net loss widens to SEK 24.49 million; net sales rise 61% to SEK 14.28 million

Reuters
·
May 07

Castle Biosciences Q1 Adj. EPS $(0.49), Inline, Sales $83.700M Beat $79.415M Estimate

Benzinga Earnings
·
May 07

BRIEF-Castle Biosciences Q1 Revenue USD 83.679 Million Vs. IBES Estimate USD 79.4 Million

Reuters
·
May 07

Castle Biosciences Q1 Pretax Profit USD -14.413 Million

THOMSON REUTERS
·
May 07

Castle Biosciences Q1 EPS USD -0.49

THOMSON REUTERS
·
May 07

Castle Biosciences says Mayo Clinic data show TissueCypher shifts Barrett’s surveillance intervals 55%

Reuters
·
May 04

SciBase publishes 2025 annual report

Reuters
·
Apr 27

Castle Bio CEO Derek Maetzold disposes 4,450 common shares for $111,687.36

Reuters
·
Apr 24